Contribution of the macrophage migration inhibitory factor superfamily of cytokines in the pathogenesis of preclinical and human multiple sclerosis: In silico and in vivo evidences
Paolo Fagone(University of Catania), Ferdinando Nicoletti(University of Catania), Maria Cristina Petralia(University of Messina), Eugenio Cavalli(Centro Neurolesi Bonino Pulejo), Emanuela Mazzon(Centro Neurolesi Bonino Pulejo), Alessia Bramanti(University of Salerno), Yousef Al‐Abed(Feinstein Institute for Medical Research), Katia Mangano(University of Catania), Placido Bramati(Centro Neurolesi Bonino Pulejo)
Cited by 83
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508
The neuropathic pain: An overview of the current treatment and future therapeutic approaches
|International Journal of Immunopathology and Pharmacology|2019|495